

Mail Stop 6010

April 1, 2009

James B. Murphy
Vice President and Chief Financial Officer
OXiGENE, Inc.
230 Third Avenue
Waltham, MA 02451

**Re: OXiGENE, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed March 25, 2009
File No. 0-21990**

Dear Mr. Murphy:

This is to advise you that we have limited our review of the above proxy statement to the issues identified below. We will make no further review of this filing.

Where indicated, we think you should revise your document in response to these comments. If you disagree, we will consider your explanation as to why our comment is inapplicable or a revision is unnecessary. Please be as detailed as necessary in your explanation. After reviewing this information, we may or may not raise additional comments.

General

1. Please revise to disclose whether you currently have, or do not have, any plans to issue any of the additional authorized but unissued shares that would be available as a result of the approval of the any of the amendments to the Restated Certificate of Incorporation, including the increase in authorized shares of common and preferred stock and the additional authorized shares available as a result of the reverse stock split.

Proposal 3, page 9

2. Please revise your disclosure to include a discussion of the ramifications of blank check preferred stock.

Proposal 4, page 9

3. Please disclose the number of shares that will be outstanding and authorized following the reverse split assuming a 1:2 reverse split and a 1:10 reverse split.

* * *

As appropriate, please revise your proxy statement in response to these comments. You may wish to provide us with marked copies of the revised document to expedite our review. Please furnish a response letter that keys your responses to our comments. Detailed cover letters greatly facilitate our review. Please file your cover letter on EDGAR under the form type label CORRESP. Please understand that we may have additional comments after reviewing your amendment and response to our comment.

We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filings reviewed by the staff to be certain that they have provided all information investors require. Since the company and its management are in possession of all facts relating to a company's disclosure, they are responsible for the accuracy and adequacy of the disclosures they have made.

In connection with responding to our comments, please provide, in writing, a statement from the company acknowledging that

- the company is responsible for the adequacy and accuracy of the disclosure in the filings;
- staff comments or changes to disclosure in response to staff comments in the filings reviewed by the staff do not foreclose the Commission from taking any action with respect to the filing; and
- the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

In addition, please be advised that the Division of Enforcement has access to all information you provide to the staff of the Division of Corporation Finance in our review of your filing or in response to our comments on your filing.

Please contact Jennifer Riegel at (202) 551-3575 with any questions.

Sincerely,

Jeffrey Riedler
Assistant Director